News

The investigational oral agent upadacitinib was evaluated in a phase 3 clinical trial, dubbed SELECT-NEXT, in patients with moderate to severe RA who did not respond adequately to treatment with

Teva Pharmaceutical Industries announced positive results from the second Phase III HALO study of fremanezumab (TEV-48125), an investigational treatment for the prevention of migraine.  In the episodic migraine (EM)

The Prescription Drug User Fee Act (PDUFA) date is January 24, 2018. TRULANCE is a once-daily tablet approved by the FDA for the treatment of adults with chronic

Excluding Japan, Grünenthal will hold the global rights to Zomig, which is developed for the acute treatment of migraines and cluster headaches. Zomig was approved to treat migraine

Aristada is an extended-release injectable atypical antipsychotic which after entering into the body gets converted to aripiprazole. The atypical antipsychotic has now been approved by FDA in four

Stephen Hurly, President and Chief Executive Officer of Eleven Biotherapeutics said: "Despite current therapies and surgical regimens, there remains a large unmet need for patients with recurring or

The project will use AbCellera’s single-cell screening platform to profile vaccine-specific human antibodies elicited by seasonal influenza vaccination and to generate large panels of human monoclonal antibodies with

Based in Albany of New York, AMRI provides drug discovery, development, cGMP manufacturing and aseptic fill and finish services to the pharmaceutical and biotechnology industries. Under the deal, the

JCAR017 is Juno’s investigative chimeric antigen receptor (CAR) T cell product candidate that targets CD19, a protein expressed on the surface of almost all B cell malignancies, and